Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer
Status:
Suspended
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the effects (good and bad) of adding copanlisib to the usual
therapy of fulvestrant and abemaciclib in treating patients with hormone receptor positive
and HER2 negative stage IV breast cancer. Some breast cancer cells have receptors for the
hormones estrogen or progesterone. These cells are hormone receptor positive and they need
estrogen or progesterone to grow. This can affect how the cancer is treated. Hormone therapy
using fulvestrant may fight breast cancer by blocking the use of estrogen by the tumor cells.
Abemaciclib and copanlisib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Adding copanlisib to the usual therapy of fulvestrant and abemaciclib
may work better than giving fulvestrant and abemaciclib alone in treating patients with
breast cancer.